Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Wai Yuen Tong Medicine Holdings Buyback Yield % Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Wai Yuen Tong Medicine Holdings's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Wai Yuen Tong Medicine Holdings Buyback Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Wai Yuen Tong Medicine Holdings's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Wai Yuen Tong Medicine Holdings's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Wai Yuen Tong Medicine Holdings (HKSE:00897) has a Buyback Yield % of 1.14 as of Sep. 12, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Wai Yuen Tong Medicine Holdings and its competitors. This is 78% below median its historical median of 5.15. According to the industry distribution chart, Wai Yuen Tong Medicine Holdings ranks #46 out of 235 companies in the Drug Manufacturers industry, placing it in the top 19.6%.
Is Wai Yuen Tong Medicine Holdings' Buyback Yield % too high?
Wai Yuen Tong Medicine Holdings' current Buyback Yield % of 1.14 is 78% below median its 10-year median of 5.15. Based on the distribution chart, Wai Yuen Tong Medicine Holdings ranks #46 out of 235 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Wai Yuen Tong Medicine Holdings has a GF Score™ of 34/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Wai Yuen Tong Medicine Holdings' Buyback Yield % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Wai Yuen Tong Medicine Holdings ranks #46 out of 235 companies for Buyback Yield %. This places Wai Yuen Tong Medicine Holdings in the top 20% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Drug Manufacturers company?
A good Buyback Yield % depends on the Drug Manufacturers industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Wai Yuen Tong Medicine Holdings and its competitors. Wai Yuen Tong Medicine Holdings's current Buyback Yield % is 1.14, which is 78% below median its own 10-year median of 5.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wai Yuen Tong Medicine Holdings stock overvalued right now?
Based on GuruFocus' analysis, Wai Yuen Tong Medicine Holdings (HKSE:00897) is currently considered Modestly Overvalued. The stock's GF Value™ is HK$0.29, compared to a current price of HK$0.33 — trading 13.8% above its estimated fair value. The current Buyback Yield % is 1.14, which is 78% below median its 10-year median of 5.15. Wai Yuen Tong Medicine Holdings' overall GF Score™ is 34/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Wai Yuen Tong Medicine Holdings (HKSE:00897), the current Buyback Yield % is 1.14 as of Sep. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Wai Yuen Tong Medicine Holdings (HKSE:00897) Overvalued in 2026?
Based on GuruFocus' analysis, Wai Yuen Tong Medicine Holdings stock appears to be overvalued.
The current stock price of HK$0.33 is trading 13.8% above its estimated GF Value™ of HK$0.29.
GuruFocus considers Wai Yuen Tong Medicine Holdings to be Modestly Overvalued.
Key valuation signals for HKSE:00897:
Buyback Yield %: 1.14 (78% below median its 10-year median of 5.15)
GF Value™: HK$0.29 vs. price of HK$0.33 (13.8% above fair value)
No single metric tells the full story. See the HKSE:00897 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Wai Yuen Tong Medicine Holdings Ltd is an investment holding company. The company's operating segment includes production and sale of Chinese pharmaceutical and health food products; production and sale of Western pharmaceutical and health food products and property investment and management and sale of properties. It generates maximum revenue from the production and sale of Chinese pharmaceutical and health food products which include manufacturing, processing, and sale of traditional Chinese medicine which includes Chinese medicinal products sold under the brand name Wai Yuen Tong. Geographically, it derives a majority of revenue from Mainland China.
34GF Score
Get the complete analysis for HKSE:00897
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:00897 has been successfully added to your 
